Abivax
$118.37
89
+$3.4+2.96% Thursday 20:00
Statistics
Day High
119.79
Day Low
112
52W High
148.83
52W Low
4.77
Volume
952,925
Avg. Volume
1,220,642
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
25MayExpected
Expected EPS
-0.92977014306
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-367.82MNet Income
Analyst Ratings
$145.56Average Price Target
The highest estimate is 176.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 78%
Hold 11%
Sell 11%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ABVX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Merck
MRK
Mkt Cap214.76B
GSK
GSK
Mkt Cap94.51B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Abbvie
ABBV
Mkt Cap385.18B
Pfizer
PFE
Mkt Cap140.15B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Novartis
NVS
Mkt Cap237.61B
About
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
CEO
Mr. Marc M. P. de Garidel M.B.A.
Employees
69
Country
FR
ISIN
US00370M1036
Listings
0 Comments
Share your thoughts
FAQ
What is Abivax stock price today?▼
The current price of ABVX is $118.37 USD — it has increased by +2.96% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abivax stocks are traded under the ticker ABVX.
Is Abivax stock price growing?▼
ABVX stock has risen by +15.52% compared to the previous week, the month change is a +6.54% rise, over the last year Abivax has showed a +1,944.39% increase.
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on May 25, 2026.
What were Abivax earnings last quarter?▼
ABVX earnings for the last quarter are -1.22 USD per share, whereas the estimation was -1.36 USD resulting in a +10.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 USD.
What is Abivax net income for the last year?▼
ABVX net income for the last year is -367.82M USD.
How many employees does Abivax have?▼
As of April 03, 2026, the company has 69 employees.
In which sector is Abivax located?▼
Abivax operates in the Health Care sector.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, FR.